SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Alice: “The vulnerabilities we identify could affect billions if discovered by the wrong people”

Novee: “AI turns one strong researcher into something closer to a whole team”

She sold her startup to Salesforce. Then she had four kids and started another one.

The iPhone Duo is Apple’s answer to foldables. But what is the question?

Buzz

Most popular

Daily

Weekly

1

Meta loses its $1.5 billion AI recruit less than a year after hiring him

2

Secretive defense startup Covenant emerges from stealth with $250 million at over $1 billion valuation

3

Palo Alto Networks founder Nir Zuk raises $245 million for new cybersecurity startup

4

“We proved there are no sacred cows in technology”: Island founder says the company can be worth tens of billions

5

What made Anthropic walk away from the $6 billion Decart deal?

Teva Pharmaceutical Industries

6 stories about Teva Pharmaceutical Industries

מנכ"ל טבע החדש קור שולץ 2

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani

Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden

מנכ"ל טבע החדש קור שולץ 2

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17|Golan Hazani

Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month

חברת ה תרופות טבע Teva

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer

A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug

מנכ"ל טבע החדש קור שולץ

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman

Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board

Teva Sells IUD Business for $1.1 Billion

12.09.17|Lilach Baumer

Going forward, the company will focus on central nervous system and respiratory treatments, shedding its Women's Health and Oncology and Pain businesses

קור שולץ מנכ"ל טבע החדש

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld

The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated

Previous Articles